Jump to content

Landogrozumab

From Wikipedia, the free encyclopedia
Landogrozumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetGDF-8
Clinical data
Other namesLY2495655
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6338H9790N1694O1988S42
Molar mass142874.43 g·mol−1

Landogrozumab (INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.[1][2]

The drug was developed by Eli Lilly and Company.

References

[edit]
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Landogrozumab, American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).